1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hemophilia Treatment Drugs Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Types of Hemophilia Treatment Drugs
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2023–2031
6.3.1. Recombinant Coagulation Factor Concentrates
6.3.1.1. Factor VIII
6.3.1.2. Factor IX
6.3.1.3. Others
6.3.2. Plasma-derived Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Others
6.3.3. Others
6.4. Market Attractiveness, by Product
7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2023–2031
7.3.1. Hemophilia A
7.3.2. Hemophilia B
7.3.3. Others
7.4. Market Attractiveness, by Disease Indication
8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2023–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2023–2031
10.2.1. Recombinant Coagulation Factor Concentrates
10.2.1.1. Factor VIII
10.2.1.2. Factor IX
10.2.1.3. Others
10.2.2. Plasma-derived Coagulation Factor Concentrates
10.2.2.1. Factor VIII
10.2.2.2. Factor IX
10.2.2.3. Others
10.2.3. Others
10.3. Market Attractiveness, by Product
10.4. Market Value Forecast, by Disease Indication, 2023–2031
10.4.1. Hemophilia A
10.4.2. Hemophilia B
10.4.3. Others
10.5. Market Attractiveness, by Disease Indication
10.6. Market Value Forecast, by Distribution Channel, 2023–2031
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Online Pharmacies
10.7. Market Attractiveness, by Distribution Channel
10.8. Market Value Forecast, by Country, 2023–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Product
10.9.2. By Disease Indication
10.9.3. By Distribution Channel
10.9.4. By Country
11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Recombinant Coagulation Factor Concentrates
11.1.2.1. Factor VIII
11.1.2.2. Factor IX
11.1.2.3. Others
11.1.3. Plasma-derived Coagulation Factor Concentrates
11.1.3.1. Factor VIII
11.1.3.2. Factor IX
11.1.3.3. Others
11.1.4. Others
11.2. Market Attractiveness, by Product
11.3. Market Value Forecast, by Disease Indication, 2023–2031
11.3.1. Hemophilia A
11.3.2. Hemophilia B
11.3.3. Others
11.4. Market Attractiveness, by Disease Indication
11.5. Market Value Forecast, by Distribution Channel, 2023–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Attractiveness, by Distribution Channel
11.7. Market Value Forecast, by Country/Sub-region, 2023–2031
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Rest of Europe
11.8. Market Attractiveness Analysis
11.8.1. By Product
11.8.2. By Disease Indication
11.8.3. By Distribution Channel
11.8.4. By Country/Sub-region
12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2023–2031
12.2.1. Recombinant Coagulation Factor Concentrates
12.2.1.1. Factor VIII
12.2.1.2. Factor IX
12.2.1.3. Others
12.2.2. Plasma-derived Coagulation Factor Concentrates
12.2.2.1. Factor VIII
12.2.2.2. Factor IX
12.2.2.3. Others
12.2.3. Others
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Disease Indication, 2023–2031
12.4.1. Hemophilia A
12.4.2. Hemophilia B
12.4.3. Others
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Distribution Channel, 2023–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Attractiveness, by Distribution Channel
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Product
12.9.2. By Disease Indication
12.9.3. By Distribution Channel
12.9.4. By Country/Sub-region
13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2023–2031
13.2.1. Recombinant Coagulation Factor Concentrates
13.2.1.1. Factor VIII
13.2.1.2. Factor IX
13.2.1.3. Others
13.2.2. Plasma-derived Coagulation Factor Concentrates
13.2.2.1. Factor VIII
13.2.2.2. Factor IX
13.2.2.3. Others
13.2.3. Others
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Disease Indication, 2023–2031
13.4.1. Hemophilia A
13.4.2. Hemophilia B
13.4.3. Others
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Distribution Channel, 2023–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Attractiveness, by Distribution Channel
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Product
13.9.2. By Disease Indication
13.9.3. By Distribution Channel
13.9.4. By Country/Sub-region
14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2023–2031
14.2.1. Recombinant Coagulation Factor Concentrates
14.2.1.1. Factor VIII
14.2.1.2. Factor IX
14.2.1.3. Others
14.2.2. Plasma-derived Coagulation Factor Concentrates
14.2.2.1. Factor VIII
14.2.2.2. Factor IX
14.2.2.3. Others
14.2.3. Others
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Disease Indication, 2023–2031
14.4.1. Hemophilia A
14.4.2. Hemophilia B
14.4.3. Others
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Distribution Channel, 2023–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Attractiveness, by Distribution Channel
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Product
14.9.2. By Disease Indication
14.9.3. By Distribution Channel
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. CSL Behring
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Kedrion
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Takeda Pharmaceutical Company Limited
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Novo Nordisk A/S
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Bayer AG
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Octapharma AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Biotest AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Sanofi S.A.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
